Author of

• 25941

  +

  P2.04 - Immunooncology (Not CME Accredited Session) (ID 953)

  • Event: WCLC 2018
  • Type: Poster Viewing in the Exhibit Hall
  • Track:
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall

  • 26998

    +

    P2.04-21 - Real World Experience of Immune Checkpoint Inhibitors In NSCLC: Our First 10 Months Experience at Leeds Cancer Centre, UK (ID 12419)

    16:45 - 18:00  |  Author(s): Katie Spencer
    • Abstract
    • Slides

    Background
    

    Pembrolizumab and Nivolumab are monoclonal antibodies to the PD-1 receptor and have shown significant overall survival(OS) and progression free survival(PFS) in the second line setting compared to chemotherapy in non-small cell lung cancer(NSCLC). Pembrolizumab has shown significant OS and PFS in the first line setting in high PD-1 expressors(>50%).

    In January 2017, immune checkpoint inhibitors became standard of care in the UK initially in the second line setting and subsequently first line later that year.

    Studies report fewer treatment-related adverse events in the checkpoint inhibitor arm Vs chemotherapy (10-20% Vs 54%).

    We report our first 10 months experience with routine use of checkpoint inhibitors in NSCLC at Leeds Cancer Centre(LCC), UK.

    a9ded1e5ce5d75814730bb4caaf49419 Method
    

    All patients receiving pembrolizumab and nivolumb between 1/1/17 and 31/10/17 at LCC, UK were included. Retrospective review of medical notes was performed and outcomes recorded including: checkpoint inhibitor received; time to response; OS and treatment-related adverse effects. Kaplan-Meier survival curves were used to assess survival outcomes.

    4c3880bb027f159e801041b1021e88e8 Result
    

    Thirty-six patients received checkpoint inhibitors during this period. Median age was 68 years.

    Eleven patients received first line therapy with a response rate of 90% (n=10). Twenty-five patients received second line therapy with a response rate of 32% (n=8). For the whole cohort, median time to response was 52days. Median time to progression in responding patients was not reached.

    Median PFS was 152days (95%CI 57-232). Median OS was 467days (95% CI 194-not reached).

    Pseudoprogression occurred in one patient.

    Treatment-related adverse effects occurred in 58% (n=21). Of these, 57% (n=12) were non-autoimmune and 43% (n=9) were autoimmune. Grade 3-5 toxicities occurred in 8% (n=3), all were autoimmune mediated on pembrolizumab. In all cases, treatment was stopped.

    Thirty-one percent (n=11) remain on check-point inhibitors.

    8eea62084ca7e541d918e823422bd82e Conclusion
    

    Overall response rate to immune checkpoint inhibitors in this small cohort was better than reported data in both the first and second line setting (90% Vs 45% and 32% Vs 19% respectively).

    Time to response was comparable to previous trials (1.7months Vs 2.1months).

    Median PFS and OS were in keeping with large randomised controlled trials (PFS - 5months Vs 2.3-10.3months and OS - 15months Vs 12.2months).

    Frequency of treatment-related adverse effects and grade 3-5 effects were lower in this cohort at 58% and 8% respectively, compared to 69-73.4% and 10-26.6% in trials.

    In conclusion, our initial results in this real world cohort show immune checkpoint inhibitors are a safe, effective treatment in this group of patients.

    6f8b794f3246b0c1e1780bb4d4d5dc53

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.